Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging.
Autor: | Šuráňová M; Institute of Physical Engineering (IPE), Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic.; CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic., Ďuriš M; CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic., Štenglová Netíková I; General University Hospital in Prague, Department of Clinical Pharmacology and Pharmacy, Prague, Czech Republic., Brábek J; Department of Cell Biology, and Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec (BIOCEV), Laboratory of Cancer Cell Invasion, Charles University, Prague, Czech Republic., Horák T; Institute of Physical Engineering (IPE), Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic., Jůzová V; CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic., Chmelík R; Institute of Physical Engineering (IPE), Faculty of Mechanical Engineering, Brno University of Technology, Brno, Czech Republic.; CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic., Veselý P; CEITEC - Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic. |
---|---|
Jazyk: | angličtina |
Zdroj: | Biomedical optics express [Biomed Opt Express] 2023 May 16; Vol. 14 (6), pp. 2689-2708. Date of Electronic Publication: 2023 May 16 (Print Publication: 2023). |
DOI: | 10.1364/BOE.488630 |
Abstrakt: | Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented. Competing Interests: R.C. is a co-author of patents covering Q-Phase (EA 018804 B1, US 8526003 B2, JP 5510676 B2, CN102279555A, EP 2378244 B1, and CZ302491) and a recipient of related royalties from Telight. (Published by Optica Publishing Group under the terms of the Creative Commons Attribution 4.0 License. Further distribution of this work must maintain attribution to the author(s) and the published article’s title, journal citation, and DOI.) |
Databáze: | MEDLINE |
Externí odkaz: |